SLC44A4 and hypophysitis: In the study of De Filette et al. [8], hypophysitis was more common in patients treated with ipilimumab (CTL4 inhibitor) (5.6%) compared to PD-1 inhibitors (0.5–1.1%), and combination therapy was associated with a high incidence (8.8–10.5%) of hypophysitis.